Vista Scientific, LLC

Andover, MA 01810

SBIR Award Summary

Total Number of Awards 13
Total Value of Awards $3.87MM
First Award Date 04/01/99
Most Recent Award Date 09/30/10

Key Personnel

Last Name Name Awards Contact
Leahy Charles Daniel Leahy 9
Ellis Edward J Ellis 6
Crawford Kathryn S Crawford 2

13 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/30/10 - 09/29/12

DESCRIPTION (provided by applicant): The polymer platform technology and the device design developed to date offer the long- term objective of a line of products that can be worn under the eyelid for a day or for months, and useful for a number of ocular conditions that would benefit from a more sustained, controlled and inherently compliant tre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/30/09 - 09/29/10

DESCRIPTION (provided by applicant): The polymer platform technology and the device design developed to date offer the long- term objective of a line of products that can be worn under the eyelid for a day or for months, and useful for a number of ocular conditions that would benefit from a more sustained, controlled and inherently compliant tre...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-009
Budget: 08/01/09 - 01/31/11

DESCRIPTION (provided by applicant): Nanosphere technology will be utilized for controlled ophthalmic antibiotic delivery via a hydrogel polymer contact lens device. The device will be useful for a number of conditions including traumatic injury, surface disorders, and post-surgical healing. The advantage of this medicated bandage system over t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-09
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): Nanosphere technology will be utilized for controlled ophthalmic antibiotic delivery via a hydrogel polymer contact lens device. The device will be useful for a number of conditions including traumatic injury, surface disorders, and post-surgical healing. The advantage of this medicated bandage system over t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/04 - 04/30/07

DESCRIPTION (provided by applicant): The overall program objective is to define the manufacturing process for generating low cost commercially viable geometry shapes from the CMS family of highly permeable, rigid perfluoropolymer membrane materials. These shapes will be imbedded or bonded into a low cost thermoplastic polymeric frame or carrier ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 08/31/05

DESCRIPTION (provided by applicant): Using a unique polymer matrix, tailored to the chemistry of the drug, timolol, and molded into an ocular insert in a design compatible with the conjunctival sac, we will affect the release of drug for the treatment of glaucoma over a 30 to 90 day period. Customizing a matrix with such specific chemistry is an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 08/31/04

DESCRIPTION (provided by applicant): Using a unique polymer matrix, tailored to the chemistry of the drug, timolol, and molded into an ocular insert in a design compatible with the conjunctival sac, we will affect the release of drug for the treatment of glaucoma over a 30 to 90 day period. Customizing a matrix with such specific chemistry is an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/02 - 08/31/03

DESCRIPTION (provided by applicant): Using a unique polymer matrix, tailored to the chemistry of the drug, timolol, and molded into an ocular insert in a design compatible with the conjunctival sac, we will affect the release of drug for the treatment of glaucoma over a 30 to 90 day period. Customizing a matrix with such specific chemistry is an...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 03/31/03

Current modeling of the tear film acknowledges a larger presence and role of mucin in its structure and function. The objective of this application is to produce a tear supplement of natural, purified mucin, and establish its effects on the structure, stability and lubrication of the tear film, using the clinical model accepted by the FDA. No av...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 03/31/03

Current modeling of the tear film acknowledges a larger presence and role of mucin in its structure and function. The objective of this application is to produce a tear supplement of natural, purified mucin, and establish its effects on the structure, stability and lubrication of the tear film, using the clinical model accepted by the FDA. No av...

Load More